Nicole Lamanna
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 104
-
- Lymphoma Diagnosis and Treatment 62
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 17
- Immunology top 5%
- Immunodeficiency and Autoimmune Disorders 29
- Oncology top 10%
- CAR-T cell therapy research 6
-
- Acute Lymphoblastic Leukemia research 18
-
- Advanced Breast Cancer Therapies 11
-
- Childhood Cancer Survivors' Quality of Life 3
- Co-authors
- Andrew LipskyMark A. WeissSteven CoutréAndrew D. ZelenetzSusan O’BrienThomas J. KippsIan W. FlinnP. Maslak
- Journals
- Journal of Clinical Oncology (24 papers)SHILAP Revista de lepidopterología (3 papers)Blood (32 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Nicole Lamanna
107 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 67
- Genetics 1.4k
- Pathology and Forensic Medicine 1.1k
- Hematology 428
- Immunology 536
- Oncology 343
Countries citing papers authored by Nicole Lamanna
This map shows the geographic impact of Nicole Lamanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicole Lamanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicole Lamanna more than expected).
Fields of papers citing papers by Nicole Lamanna
This network shows the impact of papers produced by Nicole Lamanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicole Lamanna. The network helps show where Nicole Lamanna may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nicole Lamanna, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 11 | |
| 4 | 2023 | 8 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 0 | |
| 7 | 2021 | 2 | |
| 8 | 2020 | 33 | |
| 9 | 2020 | 6 | |
| 10 | 2020 | 5 | |
| 11 | 2019 | 2 | |
| 12 | Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial | 2019 | 1 |
| 13 | 2018 | 60 | |
| 14 | 2017 | 24 | |
| 15 | 2017 | 8 | |
| 16 | Idelalisib in Combination with Bendamustine/rituximab Improves Overall Survival in Patients with Relapsed/refractory Cll: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study | 2016 | 2 |
| 17 | 2012 | 1 | |
| 18 | 2009 | 1 | |
| 19 | 2006 | 2 | |
| 20 | 2006 | 2 |
About Nicole Lamanna
Nicole Lamanna is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology, having authored 113 papers that have together received 1.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (104 papers), Lymphoma Diagnosis and Treatment (62 papers), Immunodeficiency and Autoimmune Disorders (29 papers), Acute Lymphoblastic Leukemia research (18 papers), Chronic Myeloid Leukemia Treatments (17 papers), Advanced Breast Cancer Therapies (11 papers), CAR-T cell therapy research (6 papers) and Childhood Cancer Survivors' Quality of Life (3 papers). The work is most often cited by research in Genetics (1.4k citations), Pathology and Forensic Medicine (1.1k citations) and Hematology (428 citations). Nicole Lamanna has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Andrew Lipsky, Mark A. Weiss, Steven Coutré, Andrew D. Zelenetz, Susan O’Brien, Thomas J. Kipps, Ian W. Flinn, P. Maslak, Jalaja Potluri and Matthew S. Davids. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.